Previous close | 42.25 |
Open | 42.37 |
Bid | 42.39 x 200 |
Ask | 42.52 x 200 |
Day's range | 42.16 - 43.04 |
52-week range | 20.35 - 64.98 |
Volume | |
Avg. volume | 477,241 |
Market cap | 2.672B |
Beta (5Y monthly) | 1.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.73 |
Earnings date | 12 May 2024 - 16 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 71.00 |
SAN FRANCISCO & ZUG, Switzerland, April 10, 2024--MoonLake Immunotherapeutics ("MoonLake"; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa (HS) and active
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Biotech stock MoonLake popped Monday after the company said its experimental psoriatic arthritis treatment beat out AbbVie's Humira.